AP Biosciences, Inc.

AP Biosciences is a pioneering clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative bispecific antibodies. Leveraging our proprietary Omni-Mab Library and T-cube platforms, we design and develop smarter antibodies that target multiple pathways and enhance immune response, providing new hope for patients with difficult-to-treat cancers.

With a proven track record of rapid development from concept to clinical trials and strategic global partnerships, AP Biosciences stands at the forefront of innovation, committed to improving patient outcomes and advancing the future of oncology therapeutics.